Showing results (1251-1260 of 1,277) with videos related to

Sort By:
Pageof 128
Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 12, 2023
Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung CancersJianling Bi, Emily Witt, Megan K McGovern, et al.
Circulation|June 15, 2007
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trialDouglas W Losordo, Richard A Schatz, Christopher J White, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 9, 2020
Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United StatesSantiago Garcia, Larissa Stanberry, Christian Schmidt, et al.
Journal of the American College of Cardiology|September 13, 2023
Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art ReviewNathaniel R Smilowitz, Megha Prasad, R Jay Widmer, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research|August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomesChristopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
Journal of the American College of Cardiology|September 13, 2023
Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art ReviewBruce A Samuels, Samit M Shah, R Jay Widmer, et al.
Pageof 128